22 for the southern california life science community ...matsc.org/unprotected...

10

13

22

care

years

health

market

morepatients

2014

approach amount

bettergenetic

international

passion

digital healthplanning

sequence

venture creative employees

accessinspirational new

responsefound

develop yearthrough

innovation

successfulmedical

dialog

results

support

robust

warranted feast

using

high

dealrequired

identify

support

lowincluding

example

unique

datajobshigh

event

begin

conference

littlemedicinedrugs

opportunity close

underway

reduced systemhealthcare

benefits

scienceFDAvalue

working

important

lotway

rightbigFebruary

provides

San Diegocompany

personalizedannual

streamphaseproviding

life sciencedrive

consumersdrive

think

situation

needmarkets

besttermset

moving

ideaseven

government

therapy

togetherlarge

look

become

changes

technologies

open

goingcompetition

saw

cost

moving

window

businesscontinue

profile research

research

manyfieldmake

outcomes startahead

diagnostic maintain

criticalinvestorsbasedpartners

premium

effects

tryingearlysteady

longsignificant

pipeline

energy nowinformation

population

fundsdiseaseinsurancepharma

manystageimpact

sectorworldchange

hope

seeovergreater

defined

real

funding

next

others

forward

qualitycomecapital

rest

sharing

clinicaltailored

available

costsseeing

help

speci�cresources

individual

those

lifeeasy

remain

nonpharmaceutical

largest

trend

close

products IPOproducts

top

pricing

forces making

precisionpast

treat

space

time

answerone

�rst

allowsgiven

price

issues

use

of�ce

open

muchbiotech

moleculardevelopment

take�nd

still

wayspart

many

initial

life

energy

good

LifeLinesFor the Southern California Life Science Community

New Year Brings New Policy Challenges for Biocom

Ten Reasons You Should Attend an Event

Our 2014 New Year’s Resolutions

VoLume 23, ISSue 1 Sp r i ng 2014

(858) 452-6500 BRENT JACOBS CA LICENSE NO. 791657

GREG BISCONTI CA LICENSE NO. 1167920

TED JACOBS CA LICENSE NO. 1855220

SUCCESS STARTS WITH HIRING THE RIGHT REAL ESTATE REPRESENTATIONFrom start-ups to large pharmaceutical companies, we have an unsurpassed level of experience in advising and negotiating the best possible terms for your next laboratory facility. For the past 30 years, we have focused our career on helping companies like yours, find and negotiate leases on facilities that enhance the human experience, foster collaboration and innovation, and help attract and retain the best and brightest talent. Let us be your partner in success.

See what we can do for you: www.sdlifesciences.com

Genomatica has relied on the C&W Life Sciences team as its real estate advisor for years. Throughout our early years, C&W negotiated very flexible terms and rights. These same rights later allowed us the flexibility for an early exit and the ability to negotiate great pricing and terms for our new headquarters building. With their help, we secured a custom designed project which highlights our science and positions us for success. I highly recommend them to other life science companies.

Christophe Schilling, CEO, Genomatica, Inc.

Good NewsWelcome to our Spring 2014 edition of LifeLines. In this issue, we focus on

expectations for 2014 from the perspectives of both the Biocom staff and the industry members we serve.

I am particularly encouraged after attending the annual JP Morgan Health Care Conference in January. The climate was more upbeat than ever regarding the future of the life science industry. The conference highlighted large pharma’s growing focus on developing biological products, as well as their significant advances in creating research tools and diagnostics—successes that will serve Southern California well. So, on this positive note, I know you’ll enjoy our cover story on predictions for 2014 as much as I did.

Biocom had a very successful 2013 on the advocacy front, opening our Washington D.C. office and leading the California life science community’s Sacramento public policy efforts with our partners BayBio and CHI. This year brings a new set of challenges, such as lobbying for increased NIH funding, ensuring a positive regulatory climate in California and working with our new San Diego mayor. These are discussed by our veteran vice president of Public Policy, Jimmy Jackson.

Biocom has always been known for our aggressive and timely schedule of networking events and conferences. As you will read, the kick-off for our year is the highly successful annual Global Partnering Conference. In this issue, we’ll share the top 10 reasons to attend our events and conferences throughout the year. These events are designed to appeal to every level of your organization.

One of my favorite yearly events is the San Diego Festival of Science & Engineering, during which our companies and research institutes provide an opportunity for people throughout our community to learn more about life science and engineering, with a special focus on students. On that note, Liisa Bozinovic, the new Executive Director for the Biocom Institute has an article on the celebration of the 10th anniversary of the Life Science Summer Institute, a program that has been very successful in providing internships in life science companies for our local high school and college students.

On the membership side, I’m pleased that Biocom enlisted 120 new members in 2013, bringing our total membership to almost 600 firms. You’ll get a sneak peek at the new concierge program Biocom has created for our members to ensure that we continue to inform them about the multi-faceted benefits of Biocom membership.

Finally, our regular columnist Mandy Jackson rounds out our theme of predictions for 2014 with an article on top companies to watch. Given the diversity and depth of the life science sector that we serve, it’s difficult, if not impossible, to forecast success, but I know that you’ll find these cutting edge companies and their technologies intriguing. We’ll follow their progress, along with you, as we work to accelerate your success.

2 Cover Story: I see.... 2014

10 Public Policy : New Year Brings New Policy Challenges for Biocom

11 Members in Action: HR Conference, Breakfast Meeting

12 Members in Action: Annual Celebration of Life Dinner

13 Events: Ten Reasons You Should Attend an Event

16 Guest: San Diego Public Companies to Watch in 2014

18 The San Diego Festival of Science & Engineering - Be there!

20 Biocom Institute: Life Science Summer Institute Celebrates 10th Anniversary of Developing a Workforce Pipeline

22 Biocom Purchasing Group: Our 2014 New Year’s Resolutions

24 Premium Member Spotlights: Fisher Scientific, GE Healthcare Life Sciences, Janssen Labs, Wilson Sonsini Goodrich & Rosati

27 Biocom Board and Committees

28 Biocom Membership

edItor : Jennifer LandressCoPY edItor : Josh BaxtdeSIGN & LAYout: Arlene Arreola

V o L u m e 2 3 , I S S u e 1

WELCOMEI N t h I S I S S u e

www.BIoCom.orG

By Joe Panetta, President and CEO, Biocom

Biocom, a member driven organization is here to assist life science companies like yours to fulfill your most ambitious goals. We can help your company with saving money, advocacy, increased visibility, networking opportunities, capital development and workforce development. To learn more visit us at www.Biocom.org

Biocom LifeLines Spring 2014 1

The mood on the ground at the JPMorgan Healthcare Conference held in San Francisco each January sets the tone for the industry for the year. This year, people were downright cheerful as they basked in the unseasonably warm sunshine in Union Square. While the year looks positive from an IPO perspective, the overall forecast remains cloudy, as our industry grapples with the looming changes of the Affordable Care Act and an uncertain payer environment. In light of this uncertain forecast, Biocom asked Southern California leaders about their outlook for 2014 and what big trends they see impacting our industry this year. In the following pages read what they had to say.

Cover s tory

I See...2014Southern California’s Life Science Leaders Give their Insight on what to expect in 2014

with respect to “popular” indications, cancer therapeutics should continue to be front and center, with immunotherapies, especially antibody technologies, personalized medicine and stem cells also taking a leading role in the industry

thinkquality

forcompanies

there

is goingto

bemuch moreflexibilityinfinancingStrategic venture capital funds will continue to be the leading force in the industry, however, as liquidity is achieved via public markets, financial venture funds will make a comeback, late in the year and early in 2015.

extremely promising to see how science’s growing knowledge of genetics is beginning to have a meaningful and actionable impact on oncology

It’s

extremelypromising

see

how

science’s

growingknowledge

genetics

beginning have

meaningful

and

actionable impactoncology

This year partnering will become even more important and we’ll be seeing more deal structures that are creative and tailored to the situation

Strategic venture capital funds will continue to be the leading force in the industry, however, as liquidity is achieved via public markets, financial venture funds will make a comeback, late in the year and early in 2015.

venture

digital health

medicine

opportunity reduced

value

way

rightbig set based

science

developthrough

innovationsupporthigh

unique

bestideaseven

businesscontinue energy

seequality

come time

therapytechnologies

ahead

nowinformation

caremarketover

real

tailored

help

trend

spaceone

�rstenergy

good

pricing

priceopen�nd

togetherchanges

diseasepharma

forward

individual

forces

biotech

long

cost effects

2014

approachbetter

amountinspirational

dialogpatientsbenefits

lotFebruary

term

moving partnerspremium

system

workingphase

investors

supportincluding

underway

response

results

feast

lowprovides

San Diegobegin

annualdrive

situation

needresearch

life

think

saw window

make

diagnostic maintain

trying

available

manystage

pipeline

fundingsharing

clinical

speci�cthose

remain

nonpharmaceutical

precision

allows

easy

conferencecompetitionearlysteady

morelife

IPO

geneticdrugs

international

successfulmedical

robust

warranted

using

closehealthcare

stream

providingFDAimportant

large

creative employees

accessnewfound

year

life scienceplanning

sequence

dealrequired

identify

example

personalized

open

datajobshigh

event

little

company

consumersdrive

markets

profilecritical many

initial

passiongovernment

becomemany

field

outcomes starthealthimpact

sectorworldchange

hopegreater

capital

rest costsseeing

resources

largest

close

products

topmaking

past

treat

answer

givenissues

take

years

moving

lookgoing

research

significant

population

fundsinsurance

defined

next

others

products

use

of�ce

much

moleculardevelopment still

wayspart

Magda Marquet, Ph.D.Founder and Co-chairman, Althea TechnologiesExecutive Chair, Biocom Board of Directors

Of the dominant disruptive forces

that are currently in play in healthcare, one of the most formidable is the trend towards individualized medicine using

tools such as pharmacogenomics. Although we have been talking about it for over a decade and despite the fact that there are a few examples in oncology and cardiovascular disease, the main impact is still to come. With the staggering number of over 4 billion new prescriptions written in 2012, the need to prescribe drugs using the pharmacogenetic profile of the patient could not be more pressing. In the last couple of years the FDA itself has stepped in and listed over 200 drugs with pharmacogenomics information on their labels. There is little doubt that the impact of pharmacogenomics on the elderly patient population will be profound. Consider these two facts: adverse drug reactions are among the top five greatest threats to the health of seniors and on average, seniors take 14 (ages 65 to 69) to 18 (ages 80 to 84) prescriptions per year often concomitantly (seniors in nursing homes take on average 13 different prescriptions per day). By alerting the physician on a given patient’s ability to metabolize or absorb a given drug, pharmacogenomics will help millions avert life threatening and costly hospitalizations.

Diego Miralles, M.D.Global Head, Innovation, Janssen Pharmaceuticals

There is a lot of energy in the industry right now based on the fact that the IPO window is open, valuations have gone up and investors are returning to the space. Never has there been better science. We are entering into therapeutic spaces and modalities that we never would have

dreamed of. I really believe the possibilities are endless.A big change is the impact of molecular diagnostic in cancer.

Like we have been long doing in infectious diseases, we can identify the drugs needed to treat that specific molecular change. This results in reduced toxicity, better outcomes and reduced unnecessary costs. With a more rational use of drugs, we will have a better value proposition than we have in the past.

A big question is how quickly the system will evolve with regard to how we pay for healthcare. In the U.S. we are still able to obtain premium drug pricing that would be difficult to get anywhere else in the world. However, given the fiscal situation, how can the U.S. sustain that differential price relative to the rest of the world?

It will be challenging.To justify premium pricing, biotechnology companies are all

trying to find differentiated drugs that have a significant impact in patients. These are not easy to come by, so naturally the competition is very intense, and you have to go further upstream to have access to quality innovations at a reasonable price. This should result in more early-stage deal making in the years to come.

Carin Canale President, Canale Communications,Vice Chairwomen, Biocom Board of Directors

Open. Close. Open. Close? The back and forth banter on the state of the IPO window at the end of 2013, reminded me of my daughter wanting the car window open – her mind changes with the wind every five seconds. As 2013 came to a

close, while some predicted the end of the biotech IPO opportunity, I was steady with my forecast of an open and robust window for life

science companies in 2014. On the heels of the annual JP Morgan c o n f e r e n c e , it seems the sentiment is now quite unanimous – the window will remain open and

companies are standing in line to go public. The question is how many and for how long? Nobody knows the

answer, but what I predict is that there will be a steady drumbeat of IPOs and the best ideas – and only the best ideas – for new medicines or other medical innovations will be welcomed with open arms. What I don’t think we’ll see is the irrational exuberance of the genomics bubble, rather a market where the highs may not be as high, but the lows aren’t nearly as low. I for one am not a fan of feast or famine. I think we’ve matured as an industry and my hope for 2014 is that the market will support only those companies with real data and real opportunity for value.

Rich Heyman, Ph.D.President & CEO, Seragon Pharmaceuticals

I think for quality companies there is going to be much more flexibility in financing, and, as a CEO of a private company, my options are much greater than they were in the past.

Last year the strong companies went out at reasonable valuations and have

increased in value over time. These companies have access to

Cover s tory

“what I predICt Is that there wIll be a s teady drumbeat of Ipos aNd the best Ideas – aNd oNly the best Ideas – for New medIC INes or other medIC al INNovat IoNs wIll be welComed wI th opeN arms.” — C arIN C aNale


much more capital than they have in the last few years, putting them in an interesting position. Previously there were minimal opportunities for an exit—only M&A. The IPOs offer a potential liquidity event for investors and puts the management team in the position to either partner, or continue to go it alone because they have enough capital to fund later stage programs. This is a great thing because with this business, which is a hard business, you want as much flexibility and optionality as possible. Because of this, the mood in the industry is quite upbeat, and I don’t think that the doors are going to slam shut any time soon.

However, a concern I have is that weaker companies may try to go public, and I hope that doesn’t spoil the market. It is important that public investors do enough homework to separate between the wheat and the chaff in a meaningful way. Another thing I get a little worried about is whether the investors are going to begin investing more in early stage companies again. It’s going to be important to have venture capital firms, both private and corporate, investing in early stage technologies or the pipeline will dry up.

Lisa Haile, J.D., Ph.D. Partner, Co-Chair, Global Life Sciences Sector, DLA Piper Vice President & General Counsel, Biocom Board of Directors

Following the annual JP Morgan Healthcare conference in San Francisco the week of January 12, several trends for 2014 percolated to the top. First, for the second year in a row, the mood

was upbeat and industry leaders appear optimistic for a successful 2014. The IPO class of 2013 was one of the largest in biotech history with over 30 companies going public and 2014 should see the trend continue, assuming positive data and a low incidence of clinical failures, which tend to rattle investors. Second, with respect to “popular” indications, cancer therapeutics should continue to be front and center, with immunotherapies, especially antibody technologies, personalized medicine and stem cells also taking a leading role in the industry. In addition, RNA technologies, such as RNA interference (RNAi), should become more palatable for investors in 2014, especially with the development of new and successful delivery systems which have been needed for this field to take off. Finally, compliance and transparency have been and will continue to be key issues for global companies in 2014. The increase in internal and government investigations involving

whistleblowers and issues under the Foreign Corrupt Practices Act (FCPA) and the Sunshine Act, for example, means that companies will need to ensure they have strict risk and compliance programs in place to avoid serious charges and damaging allegations in the future.

Hillary TheakstonExecutive Director, The Clearity Foundation

We are seeing greater patient engagement and empowerment, and I think that trend will continue through and beyond 2014. People are becoming more personally involved in healthcare coverage decisions, now that

the Affordable Care Act facilitates online access to insurance information. Patients are flocking to online communities and using social networks to obtain health information and to share their experiences to help others. Through traditional and social media, patients are learning about discoveries that may dramatically change treatment. We are shifting from a one-size-fits-all approach to more personalized one. This trend will converge with more empowered patients, who will not only demand improved health outcomes, but better value for their healthcare dollar.

Harry Gruber, M.D.President & CEO, Tocagen

I believe that cancer immunotherapy will continue to make important advances this year, and ultimately lead to a fundamental shift in the treatment of cancer. This shift is reminiscent of the dramatic progress against infectious disease after the introduction of vaccines. While the invention of antibiotics was a

huge leap forward in treating pathogens, infectious diseases were only truly tamed with the advent of vaccines that elicit an immune response against the pathogen. In the same way, while small molecule drugs can be highly effective at killing cancer cells, the most important way to treat cancer will be invigorating the immune system to recognize and eliminate cancer cells.

Cancer immunotherapeutics is finally coming of age with the approval of ipilimumab for treating melanoma, Science naming cancer immunotherapy as the “Breakthrough of the Year” for 2013, and the PD-1/PD-L1 targeting antibodies racing towards approval. An additional technology involves CAR T cells, which uses gene therapy to reprogram patients’ T cells to target and destroy lymphoma cells. Other companies, including Tocagen, are also using gene therapy to harness the immune system to treat cancer. Our approach involves a tumor-selective retroviral replicating vector that delivers a therapeutic gene for an initial local antitumor effect followed by a specific, systemic antitumor immune response. Our

venture

digital health

medicine

opportunity reduced

value

way

rightbig set based

science

developthrough


unique

bestideaseven


seequality

come time

therapytechnologies

ahead

nowinformation

caremarketover

real

tailored

help

trend

spaceone

�rstenergy

good

pricing

priceopen�nd

togetherchanges

diseasepharma

forward

individual

forces

biotech

long

cost effects

2014

approachbetter

amountinspirational


lotFebruary

term


system

workingphase

investors

supportincluding

underway

response

results

feast

lowprovides

San Diegobegin

annualdrive

situation

needresearch

life

think

saw window

make

diagnostic maintain

trying

available

manystage

pipeline

fundingsharing

clinical

speci�cthose

remain

nonpharmaceutical

precision

allows

easy


morelife

IPO

geneticdrugs

international

successfulmedical

robust

warranted

using

closehealthcare

stream


large

creative employees

accessnewfound

year


sequence

dealrequired

identify

example

personalized

open

datajobshigh

event

little

company

consumersdrive

markets


initial

passiongovernment

becomemany

field


sectorworldchange

hopegreater

capital

rest costsseeing

resources

largest

close

products

topmaking

past

treat

answer

givenissues

take

years

moving

lookgoing

research

significant

population

fundsinsurance

defined

next

others

products

use

of�ce

much


wayspart

Cover s tory

“we are see ING Greater pat IeNt eNGaGemeNt aNd empowermeNt , aNd I th INk that treNd wIll CoNt INue throuGh aNd beyoNd 2014.” — h Illary theakstoN

4 Biocom LifeLines Spring 2014

lead product, Toca 511, initially kills the tumor by converting a prodrug into a potent anticancer agent within the cancer cell. These dying tumor cells then selectively stimulate the immune system to seek and destroy remaining cancer cells. This, and our other immunotherapy programs in development at our company in addition to alternative approaches at other companies, have the potential to become dramatically better tools in the fight against cancer.

Damien McDevitt, Ph.D.VP & Head of BD for R&D Extended Therapy Areas, Head of R&D West Coast Satellite Office, Worldwide Business Development, GlaxoSmithKline

The pharma industry has gotten a lot of heat in recent years about its lack of R&D productivity and innovation and the drought of new medicines available to patients. That criticism, much of which

was warranted, has led to a fair amount of soul searching about how, and with whom, we develop new medicines. The conclusion many of us have come to is that all of the available best science can’t be found within our company walls and that we must significantly increase access to external scientific and medical innovation to maintain a sustainable pipeline of novel medicines for patients.

To do this, many large pharmas are joining forces with a broad range of scientists in academia, biotech, venture firms and even other pharma companies and we saw a lot of this activity in 2013. This year partnering will become even more important and we’ll be seeing more deal structures that are creative and tailored to the situation.

A significant area of evolution is pharma’s relationship with venture capital. Many pharmas, including GSK, have become limited partners in venture funds. Moving forward you will see even more creative pharma-VC relationships develop. GSK has established a unique discovery collaboration model with Avalon Ventures to build up to 10 project-based companies together, sharing ideas and providing access to GSK technologies and resources.

Working in creative ways with partners and constructively managing relationships will be critical to developing the next generation of medicines for patients who are waiting. To do so it is critical to be where your partners are, which is why GSK set up a satellite office in San Diego in January 2014.

Standish FlemingManaging Member and Owner, Forward Ventures

The IPO window will close. I know, that sounds like a no-brainer, but in some ways this window, the first under the JOBS act, really has been different. As skeptical as I am about Washington’s ability to do anything economically constructive, they got this one right.

I’m not sure it has done anything for jobs, but JOBS has greatly improved the efficiency of the IPO process. The result has been a better selection of companies, more accurate pricing and a more durable window. But, while JOBS improves the process, those details do not drive the system. As the Fed takes away the free-money punch bowl, Wall Street will sober up and the window will close, gradually, I hope.

In 2014 we will begin to feel the full effects of Obama Care, and they will not be good for biotech or innovation. Having fumbled the Affordable Care Act kick-off (the easy part), the political establishment will now try to actually play the game (the hard part). The burden on the Federal budget will result in a shift of national healthcare priorities from investment (research) to consumption (services for 20-30 million additional enrollees). A thought for the paranoid: if the game doesn’t go better than the kick-off, Obama Care might be the prelude to a single-payer system—a low probability event but truly scary for biotech.

Jay LichterManaging Director, Avalon Ventures

Last year saw the opening of the IPO window for the first time in years, and 2014 will continue to show strong public market support for life science companies. Additional IPO’s and follow-on financings will drive the broader market as newly public companies will look to expand their product offerings via

licensing and M&A. The venture capital market will only slightly return in 2014. Strategic venture capital funds will continue to be the leading force in the industry, however, as liquidity is achieved via public markets, financial venture funds will make a comeback, late in the year and early in 2015.

venture

digital health

medicine

opportunity reduced

value

way

rightbig set based

science

developthrough


unique

bestideaseven


seequality

come time

therapytechnologies

ahead

nowinformation

caremarketover

real

tailored

help

trend

spaceone

�rstenergy

good

pricing

priceopen�nd

togetherchanges

diseasepharma

forward

individual

forces

biotech

long

cost effects

2014

approachbetter

amountinspirational


lotFebruary

term


system

workingphase

investors

supportincluding

underway

response

results

feast

lowprovides

San Diegobegin

annualdrive

situation

needresearch

life

think

saw window

make

diagnostic maintain

trying

available

manystage

pipeline

fundingsharing

clinical

speci�cthose

remain

nonpharmaceutical

precision

allows

easy


morelife

IPO

geneticdrugs

international

successfulmedical

robust

warranted

using

closehealthcare

stream


large

creative employees

accessnewfound

year


sequence

dealrequired

identify

example

personalized

open

datajobshigh

event

little

company

consumersdrive

markets


initial

passiongovernment

becomemany

field


sectorworldchange

hopegreater

capital

rest costsseeing

resources

largest

close

products

topmaking

past

treat

answer

givenissues

take

years

moving

lookgoing

research

significant

population

fundsinsurance

defined

next

others

products

use

of�ce

much


wayspart

Cover s tory

“workING IN Creat Ive w ays wI th partNers aNd CoNstruCt Ively maNaGING relat IoNshIps wIll be Cr I t IC al to developING the Next GeNerat IoN of medIC INes for pat IeNts who are w aI t ING.” — damIeN mCdev I t t


The relationship between pharma and venture capital firms and venture-backed companies should remain on new more even footing, because of the robust public markets. However, public markets can be fickle and change quickly. When this happens, venture capital and biotech companies will need to be self-reliant again. Hopefully, this won’t happen in 2014.

Steven MentoPresident & CEO, Conatus Pharmaceuticals

What’s happened over the last decade is that large pharmaceutical companies have increasingly looked to smaller drug development companies for their pipeline opportunities. Fewer companies advance drugs all the way from concept to market independently. I think what

little companies do really well is focusing on trying to get it right in the early stages. If they are successful with the preclinical and clinical development of their products, they or their products often are acquired by larger companies which then advance through regulatory approval to commercialization. That’s neither good nor bad, but does reflect the new reality in our industry.

This new reality provides a tremendous opportunity for San Diego. We have the entrepreneurial environment, infrastructure and resources – excellent research institutions and universities, venture-backed funding, as well as good trade organizations and support networks – to facilitate the startup and growth of life sciences companies. What’s special about San Diego, however, is the sense of community. People are extremely supportive. We don’t look at other companies as competitors. They’re part of the family of biotech in the San Diego region. I think that’s the reason we have so many companies positioning themselves in this industry in this location.

Jack FlorioCEO, Amplyx Pharmaceuticals

2014 will be the year that Connected Health turns the corner. We will begin to leave behind an environment with a collection of individual apps, technologies, and devices that populate consumers smart phones, computers, and phones. We are now moving into an environment where all of this technology

starts to become integrated into healthcare solutions focused on improving outcomes and lowering costs. This market will have moved from a B2C market to a B2B2C market where the adoption will be driven by payors who will be demanding demonstrated outcomes.

One key driver of this is the democratization of health care where consumers now possess a significant amount of information about

disease, their own bodies and how to restore and maintain health. Another driver is the change in the healthcare system that pushes more of the cost and the decision-making responsibility onto the consumer driving him or her to become more educated buyer and concerned about maintaining their health to lower their costs.

We will start to see an even greater integration of the biotech and pharmaceutical products of our Biocom members with the apps, technologies, and devices of the tech world working together with the focus on improving outcomes.

San Diego is in a unique position to establish itself as the epicenter of this rapidly emerging market with the strength of organizations like Biocom, Qualcomm, WLSA, West Health, Scripps Translational Science Institute and too many others to mention all working together with the common goal of demonstrating leadership in how healthcare is delivered to the consumer and more importantly how health is maintained.

Mark StevensonExecutive Vice President, Thermo Fisher Scientific & President, Life Sciences Solutions

It’s extremely promising to see how science’s growing knowledge of genetics is beginning to have a meaningful and actionable impact on oncology. Our ability today to rapidly peer into the DNA of cancerous tumors through sequencing

technology and accurately identify specific driver mutations with the aid of cancer panels is changing how oncologists treat the disease – at a very individualized level. But there is yet another evolving segment of the personalized medicine market that rivals the growth we’ve seen in oncology, and which we have every reason to look forward to in the years ahead.

Pharmacogenomics (PGx) is poised to become a booming business that also leverages genetics and sophisticated instruments, but with more immediate application. Currently, there are about 70 drugs on the market to treat conditions ranging from cardiovascular disease, depression and chronic pain, but how can doctors discern which will work best for their patients? Similar to the revolution we’re seeing in oncology, PGx leverages genetics to help doctors prescribe the right drug to the right patient. This is great news for patients, who otherwise may be given a drug that isn’t compatible with their genetic makeup, but it’s also good for

“2014 wIll be the year that CoNNeCted health turNs the CorNer.” — JaCk florIo

venture

digital health

medicine

opportunity reduced

value

way

rightbig set based

science

developthrough


unique

bestideaseven


seequality

come time

therapytechnologies

ahead

nowinformation

caremarketover

real

tailored

help

trend

spaceone

�rstenergy

good

pricing

priceopen�nd

togetherchanges

diseasepharma

forward

individual

forces

biotech

long

cost effects

2014

approachbetter

amountinspirational


lotFebruary

term


system

workingphase

investors

supportincluding

underway

response

results

feast

lowprovides

San Diegobegin

annualdrive

situation

needresearch

life

think

saw window

make

diagnostic maintain

trying

available

manystage

pipeline

fundingsharing

clinical

speci�cthose

remain

nonpharmaceutical

precision

allows

easy


morelife

IPO

geneticdrugs

international

successfulmedical

robust

warranted

using

closehealthcare

stream


large

creative employees

accessnewfound

year


sequence

dealrequired

identify

example

personalized

open

datajobshigh

event

little

company

consumersdrive

markets


initial

passiongovernment

becomemany

field


sectorworldchange

hopegreater

capital

rest costsseeing

resources

largest

close

products

topmaking

past

treat

answer

givenissues

take

years

moving

lookgoing

research

significant

population

fundsinsurance

defined

next

others

products

use

of�ce

much


wayspart

Cover s tory


business. The sophisticated platforms on the market, like those provided

by Life Technologies, are helping to drive the screening cost way down, from about $150 per test to just $12. As clinical laboratories are struggling for reimbursement dollars from the healthcare system, these molecular solutions are affording labs the opportunity to offer more of these tests while remaining profitable. PGx will prove to be the next big win in personalized medicine -- for patients and biotech.

Charles M. Baum, M.D., Ph.D.President & CEO, Mirati Therapeutics

There is a significant transformation underway in the field of oncology, not just in terms of our understanding of the biology of the disease, but also how we are conducting clinical trials. A trend we will see in clinical development

in 2014 is the selection of patient populations based on defined genetic abnormalities that make their tumors highly responsive to drugs that potently inhibit those genetic alterations. This “precision medicine” approach, like we are pursuing at Mirati, started when I was working at Pfizer on the development of Xalkori, one of the first drugs approved with a companion genetic diagnostic, and is now becoming main stream. For example, a coalition of government agencies, pharmaceutical companies, and a non-government organization have launched the “Master Protocol” study, a phase II and phase III trial to evaluate multiple drugs, assigning patients to therapy based on their specific tumor genetic profile.

The benefits of the precision medicine approach are multiple: targeting specific patient populations with distinct genetic profiles is much more efficient, allows for smaller studies involving only 150-200 patients, and provides a definitive answer much sooner as to whether or not the drug works. Most importantly, this approach allows for a treatment that is tailored to each individual patient, resulting in a greater benefit and generally fewer side effects for each patient. This is a profound step forward in the oncology space, where in the past patients were subjected to drugs with considerable toxicity without much predictability of response.

William MolloiePartner, PricewaterhouseCoopers LLP

Implementation of the Affordable Care Act (ACA) is only one of the factors forcing a rapid reshaping of the $2.8 trillion U.S. healthcare industry in 2014 according to PwC’s Health Research Institute (HRI). In its annual report on the Top Health Industry Issues for 2014, PwC’s HRI identifies the top 10 issues

facing the U.S. health sector this year. The report notes that much of the health industry has accepted

that reform is here to stay – and forward-looking executives are making decisions based on a post-ACA landscape that has altered the provision of insurance and the delivery of care.

According to HRI, 10 issues stand out as the top focus for the health industry in the year ahead:• Price transparency is growing as purchasers – consumers and

employers – are demanding and receiving more information on cost and quality

• Employers are exploring new health insurance options through private exchanges

• New regulation aims to eliminate counterfeit medications in the drug supply chain

• States are turning to managed care to help contain Medicaid long-term care costs

• All healthcare companies need to rethink their roles and business models in the new health economy

• Healthcare companies will need to change their rules on innovation — embrace “fail fast” approaches

• Social, mobile, analytics, and cloud technologies are driving new health industry business models

• Corporate venture capital is picking up the slack as traditional venture funding slows for pharmaceutical start-ups

• Technology is redefining the healthcare job market• Drugmakers must rethink their clinical trial research methods,

embracing alternative approaches

Michael BrownPartner, Stradling Yocca Carlson & Rauth

The IPO window flew wide open for life science companies in 2013, allowing San Diego life science companies to tap public markets in a meaningful way for the first time in years. Seven San Diego companies went public in 2013 year – all of them in the life sciences sector.

That’s up from one life science IPO for San Diego companies in 2012. The amounts raised in San Diego life science IPOs in 2013

“a treNd we wIll see IN Cl IN IC al developmeNt IN 2014 Is the seleCt IoN of pat IeNt populat IoNs b ased oN def INed GeNet IC abNormal I t Ies that make the Ir tumors h IGhly respoNsIve to druGs that poteNtly INhIb I t those GeNet IC al terat IoNs.” — Charles m. b aum, m.d. , ph.d.

venture

digital health

medicine

opportunity reduced

value

way

rightbig set based

science

developthrough


unique

bestideaseven


seequality

come time

therapytechnologies

ahead

nowinformation

caremarketover

real

tailored

help

trend

spaceone

�rstenergy

good

pricing

priceopen�nd

togetherchanges

diseasepharma

forward

individual

forces

biotech

long

cost effects

2014

approachbetter

amountinspirational


lotFebruary

term


system

workingphase

investors

supportincluding

underway

response

results

feast

lowprovides

San Diegobegin

annualdrive

situation

needresearch

life

think

saw window

make

diagnostic maintain

trying

available

manystage

pipeline

fundingsharing

clinical

speci�cthose

remain

nonpharmaceutical

precision

allows

easy


morelife

IPO

geneticdrugs

international

successfulmedical

robust

warranted

using

closehealthcare

stream


large

creative employees

accessnewfound

year


sequence

dealrequired

identify

example

personalized

open

datajobshigh

event

little

company

consumersdrive

markets


initial

passiongovernment

becomemany

field


sectorworldchange

hopegreater

capital

rest costsseeing

resources

largest

close

products

topmaking

past

treat

answer

givenissues

take

years

moving

lookgoing

research

significant

population

fundsinsurance

defined

next

others

products

use

of�ce

much


wayspart

Cover s tory


totaled approximately $465 million, with Tandem Diabetes raise of $138 million being the largest.

Many San Diego companies have taken steps to go public in 2014, including Biocept, Celladon, Vital Therapies, and Auspex, all of which filed S-1s with the SEC in 2013. Also, with the JOBS Act’s allowance of confidential registration statements, there may be several more San Diego life science company IPOs already underway not yet known to the public.

The degree to which the public market window for this sector will remain open in 2014 depends largely on the performance of these newly public companies. In San Diego, life science firms that went public in 2013 posted mixed results. Shares of four of the seven companies, Tandem Diabetes, Fate Therapeutics, Ambit Biosciences and Receptos are trading above their initial offering price. Shares of three companies are trading below their initial offering price.

Shawn PynesDirector of Employee Benefits, Barney & Barney

Starting January 1, 2014, the major portions of the Affordable Care Act (ACA) went into effect. Now, businesses with 50 or more full-time employees need to start executing a strategy to address the unprecedented operational and financial challenges posed by the new law.

To get out in front of the changes and stay afloat in the competitive life science industry, employers need to do the following:

• Model the anticipated health care costs to understand the financial hit you may face. Calculating all of the costs, including the less obvious ones, is critical to having a comprehensive understanding of the financial implications.

• Determine the best approach to providing health benefits based on your expense structure and needs. Will your organization “Pay” or “Play” beginning in 2015? Life Science employers need to understand the impact their strategy could take on attracting and retaining employees.

• Decide whether a defined contribution plan is the best way to proceed, including whether to participate in an insurance exchange. This method re-engages employees in the economics of health care by encouraging them to shop for benefits just like any other product.

The ACA represents the most sweeping changes to benefits since the passage of Medicare. Preparing for the big challenges ahead will set you apart from competition and ensure long-term sustainability.

Joe PanettaPresident and CEO, Biocom

After years of testing the mood at JP Morgan - was last year good, was last year bad, will this year be good or bad, will the IPO window stay open or will it close – my take away this time was that we’re moving toward greater stability in the healthcare markets, and that’s a positive thing. Healthcare as an overall

market was up 60% last year. So, my first takeaway on the future from JP Morgan was, if

Obamacare is so bad wouldn’t the opposite be happening? So setting aside health insurance politics, pharma and healthcare providers are realizing is that we’ll have more insured individuals under much more comprehensive requirements for healthcare plans, with pre-existing conditions included. Add to that the drive to bring costs down for providers and the impact of personalized medicine – diagnostics, digital health products, scanning equipment, etc.—the importance of these sectors comes into play as well.

My second takeaway was that the future is clearly in biotech and biologics with regard to big pharma R&D. In fact, one point that made an impression on me was that this year for the first time, more than half of the products in development by big pharma will be biologics. We are already experiencing the benefits of this movement in San Diego, with acquisitions and partnerships by GSK, AstraZeneca and Cubist resulting in the establishment of their continued presence here as a result. As for the question of whether the IPO window will remain open or will close, that is no longer a matter of whether biotech is “in favor”. For the foreseeable future it is because the need will be there.

“the future Is Clearly IN b IoteCh aNd b IoloGICs wI th reGard to b IG pharma r&d” — Joe paNet ta

venture

digital health

medicine

opportunity reduced

value

way

rightbig set based

science

developthrough


unique

bestideaseven


seequality

come time

therapytechnologies

ahead

nowinformation

caremarketover

real

tailored

help

trend

spaceone

�rstenergy

good

pricing

priceopen�nd

togetherchanges

diseasepharma

forward

individual

forces

biotech

long

cost effects

2014

approachbetter

amountinspirational


lotFebruary

term


system

workingphase

investors

supportincluding

underway

response

results

feast

lowprovides

San Diegobegin

annualdrive

situation

needresearch

life

think

saw window

make

diagnostic maintain

trying

available

manystage

pipeline

fundingsharing

clinical

speci�cthose

remain

nonpharmaceutical

precision

allows

easy


morelife

IPO

geneticdrugs

international

successfulmedical

robust

warranted

using

closehealthcare

stream


large

creative employees

accessnewfound

year


sequence

dealrequired

identify

example

personalized

open

datajobshigh

event

little

company

consumersdrive

markets


initial

passiongovernment

becomemany

field


sectorworldchange

hopegreater

capital

rest costsseeing

resources

largest

close

products

topmaking

past

treat

answer

givenissues

take

years

moving

lookgoing

research

significant

population

fundsinsurance

defined

next

others

products

use

of�ce

much


wayspart

Cover s tory

specialsan diegoabout

what’s is thesense ofcommunity


discover true partnership

“BioMed Realty is a trusted partner to Regulus - their entrepreneurial spirit and focus on supporting

the life science industry are key drivers of growth to us and the San Diego community.”

— Kleanthis G. Xanthopoulos, Ph. D. President & Chief Executive Officer, Regulus Therapeutics

biomedrealty.comFor more information contact Tracy Murphy at 858 207 5931 @biomedrealty

BMRC-0165-0114_Life Line Partnership Ad_D6c.indd 1 1/31/14 2:56 PM

Looking back, 2013 was a year of great change and accomplishment for the Biocom public policy team. First, we opened a full time Washington D.C. office. Within 11 months, our lobbyist helped develop federal legislation that gave biorenewables companies access to funding through the Biorefinery Assistance Program. We also coordinated a letter, signed by 30 regional life science associations, which made the sequestration of FDA funding more relevant to an overwhelming majority of Congress and their constituents.

On the state level, Biocom was a key player in helping Governor Jerry Brown pass his economic development proposal. The legislation included a state sales tax exemption for equipment used in life science manufacturing, as well as R&D, one of the only industries to get an exemption on R&D equipment. Biocom also stopped all state legislation categorized as “priority oppose.”

Many of you were able to meet Governor Brown in person as he joined us at the 2013 Biocom Annual Dinner in November.

In the final days of 2013, the Biocom board of directors voted unanimously (among those casting a vote) to endorse Councilmember Kevin Faulconer’s candidacy for Mayor of the City of San Diego. Mr. Faulconer has been a great friend and advocate for the life science industry in his time on the city council.

The life science industry spends most of its time looking forward, not back. This year, Biocom, with report partner PWC, will once again distribute its survey on the relationship between the industry and the FDA. We hope you will take the time to complete it so we have the highest quality data to take to the agency and policymakers as they begin looking at what worked in the user fee authorizations of 2012 and what needs to be addressed in the next round of user fee negotiations.

This year will also carry many challenges. As an election year, most observers do not expect a great deal of substantive new policy work to come out of Washington D.C. But as budget writers continue to look for sources of revenue to pay for federal programs, the life science industry is always at risk.

The Affordable Care Act will continue to roll out, likely with both opportunities and obstacles for Biocom member companies. The FDA will also continue to implement the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA), and continue to issue new guidances. Unfortunately, there are those who are working to erode intellectual property protections for innovators, even after the passage of the America Invents Act in 2011. Your Biocom Washington D.C. lobbyist will continue to

engage on these and many other issues.On the state level, the day-to-day implementation of the

Affordable Care Act will be a key issue, especially as so many states look to California as a leader in managed care implementation. Coverage and access to appropriate therapeutic options will be paramount. Several local governments around the country have enacted, or are considering, prescription drug and combination product take-back programs, mandating that the pharmaceutical/biotherapeutic industry bear the entire cost for these programs. Preventing a labyrinth of different programs will be a priority.

At the local level, Biocom is working with many other stakeholders to repeal the massive increase in City of San Diego affordable housing fees charged to developers and landlords, as well as engaging with local regulatory agencies as their proposals affect the industry.

You can keep up with these subjects and all other policy issues being worked on by Biocom by going to the revamped Biocom policy section at www.Biocom.org/public_policy.

Jimmy Jackson is the Vice President of Public Policy for Biocom. He oversees government affairs and public policy for the organization.

publ IC pol ICy

New Year Brings New Policy Challenges for Biocom

By Jimmy Jackson, Vice President of Public Policy, Biocom


members IN aCtIoN

BREAKFAST MEETING: Joe Panetta of Biocom, Ken Baldwin of Ferguson Pape Baldwin Architects and Supervisor Dave Roberts; Michele Yelmene of Pharmalink Consulting, EJ Brandreth of Ajinomoto Althea and John F. Wood of Arena Pharmaceuticals, Inc.

BREAKFAST MEETING


members IN aCtIoN

ANNUAL CELEBRATION OF LIFE DINNER. Clockwise from left: California Governor Jerry Brown; Heidi Chokeir of Canale Communications, Joe Panetta of Biocom and Cammy Duong of Canale Communications; Kareem Dossa of VWR toasting to the success of the life sciences industry in 2013; Keynote Speaker Jill Bolte Taylor; The Biocom Team: Michelle Wright, Katelyn Doyle, Jennifer Landress, Ashleigh Berry, Jane Zeyak and Heather Ramsay; Chuck Cashion, Paulina Chatfield and Don Ripley of Conatus Pharmaceuticals.

ANNUAL CELEBRATION OF LIFE DINNER

Photos : JT MacMillan Photography


It is easy to become swamped by day-to-day tasks, making it difficult to escape from the office for a few hours, let alone an entire day, for a business event or conference. Still, the take-home can be tremendously valuable. Events and conferences can be your resource for success, both personally and professionally. Here are my top 10 reasons you should attend some of Biocom’s events and conferences this year.

1. Networking: Social media outlets, while extremely beneficial in this era of online communication, make it way too easy to neglect actual face time. Attending a business event encourages you to interact with like-minded individuals within the industry and get talking. Biocom events help individuals create an extensive network of fellow professionals in the life science industry. To ensure valuable networking time, Biocom hosts quarterly breakfast meetings that offer a dedicated hour of networking before the panel discussion.

2. Learning: This industry is constantly growing and changing. Attending business events helps keep you up-to-date on the latest trends. Not only does learning about the industry enhance your skill set, it also allows you stay in contact with others. Biocom advances your knowledge by offering programs on the unique challenges faced by life science companies.

3. Events can be fun!: Not every event has to be all work and no play. Corporate events can be fun as well. Evening events and full-day conferences typically end with a reception, which includes food and drinks. Biocom members receive complimentary drink tickets at these networking forums. This atmosphere can make networking much more approachable. Furthermore, Biocom often includes themes and added elements at our casual receptions to excite your interest. Biocom is currently in our 4th year of hosting an evening networking gala that includes whisky, tequila and wine tastings, along with a professional cigar roller. The cigar is yours to keep.

4. Hear from Industry Experts: Event attendees not only have the opportunity to learn from industry experts, but can also interact with them directly following their panels. Sitting in on the panel sessions also gives you the opportunity to ask these industry leaders questions about the panel topic. Every panel has a Q&A portion, during which we open the floor to all guests. Questions from the audience are invaluable, as they provide opportunities to learn from your peers.

5. Find inspiration: Don’t get caught up in the same day-to-day work routine and lose focus. Networking and interacting with others is a great way to bounce fresh ideas off each other and regain that inspiration. You will leave with handouts and notes,

new resources and hopefully new perspectives. 6. Increase your visibility: Attending an event increases visibility

for both you and your company. Each time you share your business card, you are creating new contacts that can be valuable for both your personal and professional growth.

7. Discover new opportunities: Attending business events is a great way to market yourself if you are trying to get hired within the industry or looking to attract top talent on behalf of your organization. Events are a wonderful tool to connect and evaluate new opportunities.

8. Stay competitive: More than likely, your competitors are attending the same events you are. Speak with these companies. Observe how other attendees are responding to them. This helps you observe firsthand what their strengths and weaknesses are and allows you to gain a competitive edge.

9. Experience new venues: Attending an event is a fun way to discover new restaurants and venues in your city. Allow Biocom to introduce you to the newest locations and indulge in gourmet food and beverages. Typically, event planners have access to unique locations that you might not be able to experience otherwise. Last summer, Biocom hosted an evening reception at the members-only University Club that overlooks downtown San Diego. Biocom has also hosted multiple evening receptions at the Evans Garage, an antique and classic car museum that is closed to the general public. This year, you can expect more exciting receptions at new or specialized venues.

10. High-caliber speakers: Attending larger conferences and events gives you an opportunity to hear from celebrities and high-caliber community speakers you might not hear otherwise. In the past, Biocom has hosted Governor Jerry Brown, as well as famous TED speakers Jill Bolte-Taylor, Montel Williams, John Crowley and Bob Saget, to name a few.

With numerous events and industry conferences to choose from, it can be overwhelming and time-consuming to attend them all. It is not necessary to attend every event that comes your way, but attending several throughout the year can help you immensely on your path to professional growth.

Ashleigh is the Associate Manager of Events for Biocom and is in charge of organizing and marketing Biocom events.

eveNts

Ten Reasons You Should Attend an Event

By Ashleigh Berry, Associate Manager of Events, Biocom


ISO 9001:2008 CERTIFIED

TRUSTED BY LEADERS

Since 2002, Prudential Cleanroom Services and Prudential Overall Supply continues to provide BIOCOM Members reusable textile products and services for rental, lease and direct purchase programs.

Premier Supplier in the

A DIVISION OF PRUDENTIAL OVERALL SUPPLYWWW.PRUDENTIALUNIFORMS.COM 800-767-5536

Purchasing Group

BIOCOM Lifelines ads 2014 POS and PCS.indd 1 2/11/2014 4:11:23 PM

PRUDENTIAL ISDEDICATED TO SUSTAINABILITY

THE RIGHT CHOICE

PRUDENTIAL IS. . .

CAREER & CASUAL FACILITY PRODUCTS PROTECTIVE APPAREL MEDICAL APPARELCULINARY APPAREL NAPKINS TOWELS MOPS & BUCKETSRESTROOM PRODUCTS CLEANROOM MATS

800-767-5536 WWW.PRUDENTIALUNIFORMS.COM


Purchasing Group


ISO 9001:2008 CERTIFIED

TRUSTED BY LEADERS

Since 2002, Prudential Cleanroom Services and Prudential Overall Supply continues to provide BIOCOM Members reusable textile products and services for rental, lease and direct purchase programs.


A DIVISION OF PRUDENTIAL OVERALL SUPPLYWWW.PRUDENTIALUNIFORMS.COM 800-767-5536

Purchasing Group


San Diego’s biotechnology cluster will be a newsworthy group in 2014, with several companies on track to achieve research and regulatory milestones for drug candidates in their pipelines.

While the region lost some long-time biotech industry members to acquisitive companies in 2013, stock market gains and initial public offerings (IPOs) gave other businesses the resources they needed to grow.

Cubist Pharmaceuticals bought the antibiotic developers Trius Therapeutics and Optimer Pharmaceuticals for more than $1.2 billion plus future milestone fees. But while decision-making responsibilities for Trius and Optimer have shifted from San Diego to Lexington, Mass., many local biotech firms showed their staying power in 2013.

Antisense drug developer Isis Pharmaceuticals strengthened its presence in Carlsbad with a 268 percent increase in its stock price between January and December, bringing its market capitalization to $5.6 billion as of January 21. The company had more than $625 million in cash at the end of 2013 to support its development pipeline, which includes five drug candidates that could be submitted for U.S. Food and Drug Administration (FDA) approval by 2018.

Isis’s partner Genzyme launched the homozygous familial cholesterolemia drug Kynamro (mipomersen sodium) in 2013. Isis also reported positive data from 10 clinical trials for five different antisense drugs, initiated one new Phase III and five new Phase II trials and added four new drug candidates to its pipeline.

“Those successes set the stage for even more success in 2014 and more to follow,” Isis chairman and CEO Stanley Crooke said during his presentation on January 13 at the 32nd Annual JP Morgan Healthcare Conference in San Francisco.

The high-profile JP Morgan conference has become the annual kickoff event for the life science industry. This year’s conference was the first time Helen Torley spoke at a major investor event as the new president and CEO of Halozyme Therapeutics, another mainstay San Diego biotech company.

Dr. Torley said 2014 will mark a transformation for Halozyme as it shifts from enabling subcutaneous versions of intravenous medicines on behalf of its partners to producing novel therapeutics for the company’s own portfolio.

“No longer the royalty platform story, we are transforming into

a products company as well with a diversified pipeline,” she said on January 16.

Halozyme will announce clinical trial enrollment progress for the anti-cancer agent PEGPH20 during the second half of 2014. The company also plans to report top-line data during the first quarter for Hylenex, which treats type 1 diabetes, and from a Phase II cellulite study with HTI-501. In terms of partnered programs, the FDA should make an approval decision for Baxter’s HyQvia by mid-2014. Also, a European Medicines Agency (EMA) committee is expected to make a recommendation for Roche’s subcutaneous MabThera this year.

Orexigen Therapeutics has marketing applications pending in the U.S. and Europe. The San Diego-based company should have an FDA decision by June 20, and an EMA recommendation by the fourth quarter of 2014, for its obesity drug Contrave (naltrexone SR/bupropion SR).

Orexigen’s prescription weight loss therapeutic will compete with Belviq (lorcaserin) from San Diego-based Arena Pharmaceuticals. Arena’s partner Eisai launched Belviq in the U.S. on June 11 and Vivus of Mountain View, California began selling its obesity drug Qsymia (phentermine and topiramate) in September 2012.

The competition between the obesity drug developers garnered a lot of attention in 2013, and that’s not likely to change in 2014, as Orexigen nears U.S. and European approvals.

But the biggest news in biotech last year – in San Diego and elsewhere – was the open window for IPOs, which doesn’t look like it will close anytime soon.

Six San Diego-based companies were among the 38 drug developers that completed an IPO in the U.S. in 2013: Receptos, Ambit Biosciences, Conatus Pharmaceuticals, Sophiris Bio, Evoke Pharma and Fate Therapeutics.

Ambit will start a Phase III clinical trial for the acute myeloid leukemia drug quizartinib in early 2014. Sophiris will complete patient enrollment for the first Phase III trial for PRX032, to treat benign prostatic hyperplasia (BPH), during the second half of the year.

Evoke also has plans for a Phase III clinical trial to test EVK-001 (intranasal metoclopramide) to manage diabetic gastroparesis. An earlier-stage company, Fate expects to restart a Phase II trial in adult hematologic malignancies in the first half of 2014 for its

Guest

San Diego Public Companies to Watch in 2014Legacy firms and recent IPOs face important milestones

By mandy Jackson, West Coast Editor, SCRIP Intelligence


Make Your Mark in BiotechnologY

The Professional Science Masters in Biotechnology is the premier degree in San Diego. This innovative degree incorporates advanced biotechnology coursework and laboratory training with MBA-level business courses. The part-time evening program accommodates the needs of working professionals. Our graduates are well-prepared for successful careers and advancement in the life science industry.

For more information contact us at www.csusm.edu/el/degreeprograms/psmlifelines/index.html

Professional Science Master’s

HURRY!Fall 2014 Start

ApplY TodAY

hematopoietic stem cell therapy ProHema.Conatus intends to announce Phase IIb clinical trial results for

emricasan, to treat acute-on-chronic liver failure (ACLF), in the first half of 2014. The company will also initiate a Phase II trial for nonalcoholic steatohepatitis (NASH) and Phase IIb studies for chronic liver failure (CLF) and hepatitis C virus – post-liver transplant (HCV-POLT).

Finally, Receptos recently began the Phase III portion of the Phase II/III RADIANCE clinical trial for RPC1063, which treats relapsing multiple sclerosis (RMS). The company expects to start a second Phase III RMS trial after it reports Phase II RADIANCE data in mid-2014.

Mandy Jackson writes about small and mid-sized biotech companies for the biopharma news website Scrip Intelligence.

Guest

Annual Open HouseAnd Purchasing Group Supplier Showcase

Wednesday, July 23rd4-7pmBiocom Courtyard

www.biocom.org

More than 25,000 San Diegans are expected to attend the San Diego Festival of Science & Engineering (SDFSE) on Saturday, March 22 at PETCO Park. Join us there for more than 100 different hands-on activities that will excite your mind about science, technology, engineering and mathematics (STEM).

This event is geared towards children kindergarten through college but is open to anyone who wants to learn about STEM and how this industry is thriving in our own backyards. Come with your family and friends and open them up to this world and the dedication that drives our industry. The innovations of the future are being created right beside us every day. All it takes is one spark to ignite a child’s passion.

Some of those future innovators have already showed their stuff by winning a Bright Idea Society award. This program encourages schools to submit ideas for STEM-related, project-based learning. Winners are chosen from three categories: elementary, middle and high school. Each school receives a $500 stipend to bring their project to fruition, booth space at the Festival to present their activity to the community and transportation to and from the event. This annual education program is sponsored by the Kimmich Foundation, and transportation this year is being provided by the San Diego Financial Literacy Center.

SDFSE is free and open to the public thanks to our many wonderful sponsors. Some of this year’s top contributors include: ABC10 /10News & Azteca San Diego 15, Biocom, Cox Media, Jammin’ Z90 and Magic 92.5, Life Technologies, San Diego Padres, Time Warner Cable and ViaSat, Inc.

In addition, we are very excited to have three educational partners on board: The Reuben H. Fleet Science Center, The San Diego County Office of Education and University of California, San Diego. Their support, along with a host of additional sponsors, helps make this a free community event.

If you can’t make it to PETCO on the 22nd, not to worry, there are still plenty of opportunities to participate in the Festival with its week of activities throughout the county.

• Visit Taylor Guitars, where guests will tour the facility andlearn the steps of guitar construction from wood selection to final assembly.

•CheckouttheEscondidoPoliceDepartment,whichwillexposestudents to the Crime Lab and Traffic Division and how they use math and physics to complete investigations. They will showcase equipment to gather data and conduct experiments. Officers and

laboratory technicians will explain how scientific principles are used daily to solve crimes and determine how traffic collisions occurred.

•Have little ones? Visit TheNewChildren’sMuseum (NCM),where they are experimenting with food’s many possibilities in their latest exhibition, Feast: The Art of Playing With Your Food. You’ll be invited to play inside “Mold” - the museum’s one-of-a-kind building block environment made entirely of fungi. Children will have the opportunity to explore different mushroom species by creating mushroom stamp prints in a special workshop in the NCM Art Studio.

For a full listing of events, to see what’s happening in your part of town, and more information on Festival Day, please visit www.sdsciencefestival.com. We look forward to seeing you and your family during Festival Week.

Sara Pagano is the Managing Director of the San Diego Festival of Science & Engineering

sCIeNCefestIval

BE THERESan Diego Festival of Science & Engineering, March 22

By Sara Pagano, Managing Director, SD Festival of Science & Engineering

MARCHMARCH

www.sdsciencefestival.comi FRE

E

FUNEDU

CATIONA

L

MARCH 2014

SAVE THE DATE

Science, Technology, Engineering & Math

15TH-21ST

STEM Events Throughout San Diego County

22NDEXPO DAY at PETCO Park

p

e


We have advanced the artof HIPAA, FDA & UnifiedCompliance to a Science

The San Diego Workforce Partnership, in collaboration with Biocom and the Southern California Biotechnology Center at Miramar College, created the Life Sciences Summer Institute (LSSI) to strengthen science and math education and prepare people for careers in the life sciences.

LSSI programs target two populations, high school students and high school teachers. The goal is to encourage youth to explore careers in science, technology, engineering and math (STEM). LSSI was originally piloted with a Department of Labor grant. Today, it is fully supported and funded by the biotech industry. This year, LSSI celebrates its 10-year anniversary.

LSSI provides high school students with summer internships, including a one-week, pre-internship “boot camp” to prepare them for hands-on research experience. Since 2005, the program has trained and placed more than 366 students in summer research internships, working alongside Nobel Prize-winning scientists, participating in scientific talks and conducting hands-on research.

Students earn college credit for their boot camp course, receive college prep units from the University of California San Diego Extension and create a scientific poster of their work. The program has expanded to run two concurrent boot camp sessions at Grossmont College and Miramar College and maintains strong partnerships with both the Salk Institute and the Scripps Research Institute. Students from all areas of San Diego apply to be part of this highly competitive program. LSSI receives more than 300 applications per year for only 35 to 40 positions.

Jake Maskiewicz credits LSSI for his major successes. During the summer of 2010, Maskiewicz interned in a computational biology lab at the Salk Institute and has remained there ever since.

Lesly Basave, a student from a small charter school, faced many challenges including working late nights with her parents cleaning office buildings. Science was never a career option for her. However, after interning at The Scripps Research Institute she was offered part-time employment and went on to pursue a biology major. LSSI provides youth with classroom and experiential opportunities that empower them to broaden their career horizons.

In the 12-day professional development program, science teachers receive training through the Amgen Biotech Experience (ABE) curriculum and exposure to companies, such as Conatus, Genentech, Illumina, Life Technologies, Pfizer, Pharmatek, Pfenex and Sapphire Energy. By the end of the course, teachers have the skills, equipment, and supplies necessary to implement the

curriculum in their classroom. Teachers also receive first-hand knowledge about the job market, as well as the hard and soft skills needed to be successful in the biotech workplace.

The program has trained more than 180 science teachers across San Diego, Riverside and Orange Counties, impacting more than 37,000 students and sparking student excitement at scientific discovery.

The program has extended its services to Riverside County, providing materials and lab equipment for teachers. Through Miramar College’s Biotechnology program, teachers can articulate their high school biotechnology courses. More than 780 students have passed the credit-by-exam process, eliminating duplication of learning in post-secondary education.

Today, LSSI has expanded its training to include a two-week bridge program. The Introductory Life Sciences Experience (ILSE) was first piloted in 2009 to provide students experiencing economic and social barriers with direct exposure to the life sciences industry through hands-on laboratory training, interactions with scientists and visits to biotechnology sites across San Diego.

The program has trained more than 70 students and has ignited their interest in STEM-related opportunities. Students taking part in these programs have received scholarships, have been accepted into Ivy League universities and have become gainfully employed in science-related fields. LSSI has been a vehicle to help decrease the region’s gap in STEM employment.

The program’s application period is currently open and information can be viewed at www.matsc.org. Become part of the LSSI team by hosting teachers, hiring an intern or providing student sponsorships.

For more information, contact Erika Aranguré, San Diego Workforce Partnership, at [email protected]. This is your opportunity to help promote STEM education by supporting a well-established program with 10 years of proven success.

Liisa Bozinovic is the Executive Director of the Biocom Institute and also heads Biocom’s HR initiative.

bIoComINst I tute By Liisa Bozinovic,

Executive Director, Biocom Institute

Life Science Summer Institute Celebrates 10th Anniversary of Developing a Workforce Pipeline


www.Biocomconcierge.org

ALWAYS HELPFUL. ALWAYS RELIABLE. Every company requires help along the path to success. Finding service providers you can count on can be time-consuming and difficult. Let us help you by connecting your needs with the services of a trusted fellow Biocom member.

As we close the chapter on one of our most successful years to date, we’d like to take this opportunity to extend our heartfelt gratitude to our members for their participation in our contracts. This participation has allowed us to attract industry-leading suppliers to our RFPs, secure stronger price concessions and bring more robust contract offerings. Your willingness to be a team player has led to unparalleled savings and services for all our members.

With last year’s appointment of our quality control specialist, we were finally able to deliver on the increased contract compliance and quality control systems that our members have requested. Together with our expanding member base of qualified professionals, we completed our first successful circuit of advisory committees for all six contract areas.

We have honed in on five major goals for 2014, and with your assistance, we expect to knock these out of the park. 1. Save You Even More Time and Money

The Biocom Purchasing Group saved members more than $60 million in 2013, up from $48 million in 2012. One contributor to this increase was our partnership with Barney & Barney’s Beyond Benefits program: the first-of-its-kind health care trust that helped our members leverage the positive health risk of the life science industry. Since its inception, more than 88 members have joined, saving more than $2.3 million.

In 2014, we’re setting the aggressive goal of saving Biocom members more than $75 million. This benchmark is inspired by our members and reflects the commitment we have to you. 2. Add More of the Services You Need

It is hard to believe that, with more than 40 suppliers in our savings portfolio, we still have not accounted for all your procurement needs. With last year’s introduction of new member surveys, formal feedback systems and member retention meetings, however, we were able to identify three contract areas for which we plan to conduct RFPs in 2014-2015. Be on the lookout for RFP committee invitations for mobile communications, e-procurement tools and domestic airlines. As always, please do not hesitate to contact us with suggestions at [email protected]. 3. Enhance Our Communication Channels

Another takeaway from our recurring advisory committee meetings is the concept of hosting bi-annual conference calls/webinars to discuss current suppliers, prospective contract areas and the industry’s competitive landscape. The Biocom Purchasing

Group always operates in the best interest of our membership. However, the possibilities are endless when we can collaborate with more than 600 member companies to address key focus areas and create plans for the future. Our first call is scheduled for May 2014, and we look forward to hearing from you.4. Incorporate More Value-Added Benefits

Last year’s introduction of our Supplier Event Series was a huge success, consolidating events for our members and forging stronger, industry-specific partnerships. We will continue to press on our suppliers to offer additional value-added services at low or no cost to you. Veolia, our endorsed waste management supplier, is starting the trend this summer with their complimentary RCRA & DOT 2-day training and certification program. For all Biocom members who work at or oversee hazardous waste operations, we strongly encourage you to take advantage of these free resources and industry-mandated certifications.5. Expand the Biocom Travel Network

The Biocom Travel Network is a full-service program, offering members exclusive access to competitive, high-volume discounts to destination hotels, travel booking tools and air and ground transportation programs, regardless of their company size or travel frequency. We also have a heavily discounted contract lined up with Concur, the travel and expense management supplier of choice with many member companies, offering integrated solutions for travel bookings and policy and regulatory compliance. In 2014, we plan to aggressively pursue additional hotel discounts in Boston, New York City and Washington, D.C. Our goal is to create a comprehensive travel program that strengthens business for our members in San Diego and beyond.

We thank you all for your continued support and look forward to serving your procurement needs for many years to come.

Rick oversees membership and sponsorship efforts, business development opportunities, and the Biocom Purchasing Group.

purChasING Group

Our 2014 New Year’s Resolutions

By rick Fultz, Managing Director, Biocom Purchasing Group


Biocom Charity

Monday April 21, 2014 The Santaluz ClubGolf Tournament

BENEFITING:

Gourmet

dinner

Golf Pro

Trick Shot

Show

Hole

in One

Contests

San Diego craft

brew tastings

Silent

Auction

And much

much

more........

SPONSORED BY:

Biocom Charity

Monday April 21, 2014 The Santaluz ClubGolf Tournament

Space is limited and registration

is f illing up fast! Sign up today to

secure your place.

www.Biocom.org

Name: david SanbornJob title: Sales Specialist

Favorite movie: the Good, the Bad and the uglyFavorite book: “1421”Favorite quote: “do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” BuddhaFavorite TV show: Star trek; the Next GenerationFavorite restaurant or meal: Saffron in mission hillsFavorite city: San diegoFavorite actor/actress: Clint eastwoodFavorite thing to do on the weekends: events and outdoor activities with my familyWhat CD can we find in your car: John Butler trioFavorite hobby: working in the yardFavorite website: Ge Life SciencesFavorite spot in Southern California: torrey Pines State Beach ParkFirst job: research Scientist at thomas Jefferson universityFavorite part of your job: meeting and working with scientists in southern CaliforniaIf you could have another career, what would it be: National Park rangerWhy did you start working in your industry: Interest in human physiology

Name: Bill YangJob title: Vice President Sales, west region

Favorite movie: She wore a Yellow ribbonFavorite book: the Complete Far Side, Volume I and II”, Gary LarsonFavorite quote: “Be civil to all; sociable to many; familiar with few; friend to one; enemy to none’. Benjamin FranklinFavorite TV show: Big Bang theoryFavorite restaurant or meal: Stella Alpina osteria (Italian) in the Bay AreaFavorite city: madridFavorite actor/actress: John wayne/ diane KeatonFavorite thing to do on the weekends: Spending time with family and friendsWhat CD can we find in your car: toby Keith “unleashed”Favorite hobby: BicyclingFavorite website: www.facebook.comFirst job: First non professional job: Paper route. First professional job: Sales representative at American Scientific ProductsFavorite part of your job: Building relationships with our customers, learning about their research and contributing to their discoveries and successes.If you could have another career, what would it be: VeterinarianWhy did you start working in your industry:A fascination with science at a young age. I remember sitting on the floor, encyclopedias spread all around me and being amazed at everything that had been discovered and all that was still left to be discovered.

premIum member spotlIGhts

www.fishersci.com

www.gelifesciences.com

AbbVie*Ajinomoto AltheaAlexandria real estate equitiesArena PharmaceuticalsBayer healthcareBiomed realty trustBioserv CorporationBiospaceBP BiofuelsCadence Pharmaceuticals*California manufacturing technology

ConsultingCanale CommunicationsCelgeneCoI PharmaceuticalsConatus PharmaceuticalsCooleyCounty of San Bernardino economic

development AgencydeloittedLA Pipereli Lillyernst & YoungFerring research InstituteFisher ScientificFoley & LardnerGe healthcare Life SciencesGenoptixhologicJanssen research & developmentJones dayKPBSLatham & watkinsLife technologiesmentusmerck research Laboratories of San diegomintz, Levin, Cohn, Ferris, Glovsky and PopeoNuVasivePatheonPfizerPraxair*PwCVwr Internationalwilson Sonsini Goodrich & rosati

premIum members

* New members from october 2013 to January 2014


Name: dan KoeppenJob title: Partner

Favorite movie: Goodfellas, Something Ventured, and toy Story 2Favorite book: “when Pride Still mattered : A Life of Vince Lombardi” and “howard B. wigglebottom Learns to Listen”Favorite quote: “Never mistake activity for achievement” – John woodenFavorite TV show: the wire, Sopranos, Sons of Anarchy, Breaking Bad, house of Cards, and Jake & the Never Land PiratesFavorite restaurant or meal: o’Sullivan Bros. Brewing Co. tasting room & Beer Garden (coming in 2014)Favorite city: San diegoFavorite actor/actress: Ian daleFavorite thing to do on the weekends: Play basketball and spend time with my wife and two kids.What CD can we find in your car: Something from the 90’s like “monster Ballads” because that’s the last time I bought a Cd.Favorite hobby: Basketball, skiing, and watching the Green Bay PackersFavorite website: www.espn.com and www.jsonline.com/sportsFavorite spot in Southern California: Sage Canyon ParkFirst job: Cedarburg (wI) department of Public worksFavorite part of your job: Being able to help entrepreneurs create valuable products and services and have successful exits.If you could have another career, what would it be: high school basketball coach and history teacher.Why did you start working in your industry: It was my desire to be able to have an influence in building and growing companies that create novel products and services that affect people’s lives.

premIum member spotlIGhts

www.wsgr.com

With our premium membership you get increased visibility and added value to your membership. We offer our premium members maximum exposure opportunities and access to exclusive events in the life science community.

To become a premium member contact: Kira Jenkins, Director of [email protected] or 858.455.0300 x117

BECOME A PREMIUM MEMBER TODAYCompany logo seen by 100,000 life science professionals.

Company news briefs and event announcements sent to over 360,000 people annually.

Additional discounts offered at key conferences

An employee featured in LifeLines Magazine

Direct access to 15,000 people through a targeted email blast.

And many more......

Name: Kara Bortone, PhdJob title: head of Company Sourcing

Favorite movie: AmélieFavorite book: one thousand Splendid Suns by Khaled hosseiniFavorite quote: “take your work seriously, but never yourself” – margot FonteynFavorite TV show: 30 rockFavorite restaurant or meal: Fish tacosFavorite city: BarcelonaFavorite actor/actress: Audrey hepburnFavorite thing to do on the weekends: Cook a big meal and enjoy it with friends and familyWhat CD can we find in your car: London Calling – the ClashFavorite hobby: mountain bikingFavorite website: YoutubeFavorite spot in Southern California: Santa monicaFirst job: rollerblading Subway Sandwich Artist at the boardwalkFavorite part of your job: meeting entrepreneurs that are dedicated to pushing the edge of what is possibleIf you could have another career, what would it be: ArchitectWhy did you start working in your industry: I wanted to be at the interface of science and business and be a part of delivering life changing solutions to patients.

www.janssenlabs.com


board of dIreCtors

CommIttee leadershIp

BOARD OFFICERS AND EXECUTIVE COMMITTEE:ChAIr: Magda Marquet, Ph.D., Ajinomoto Althea* VICe ChAIr: Carin Canale-Theakston, Canale Communications*ChAIr eLeCt: Theodore Schroeder, Cadence Pharmaceuticals*VICe PreSIdeNt ANd GeNerAL CouNSeL: Lisa Haile, Ph.D., DLA Piper*VICe PreSIdeNt – FINANCe: Daniel Kleeburg, Ernst & Young*VICe PreSIdeNt ANd SeCretArY: Brent D. Jacobs, Cushman & Wakefield*VICe PreSIdeNt – INduStrY: Daniel BurgessChAIr emerItuS: David Webb, Ph.D.*PreSIdeNt & Ceo: Joe Panetta, Biocom*Scott Biel, Mintz, Levin, Cohn, Ferris, Glovsky & PopeoRemi Brouard, M.D., Sanofi R&D West CoastMichael Brown, Stradling Yocca Carlson & RauthTerrance J. Bruggeman, BioTork, LLCTimothy CaulfieldDaryl Dorcy, AbbVieJohn M. DunnGeoffrey S. Eich, AmgenStephen Ferruolo, J.D., Ph.D., USD School of Law*M. Wainwright Fishburn, Jr., Cooley LLP*Don Fitzgerald, GenentechJack Florio, Brinson Patrick SecuritiesGregory FrostAlan Gold, BioMed Realty TrustJeffrey W. Guise, Ph.D., Wilson, Sonsini, Goodrich & RosatiTerry Gregg, DexcomJason Hannon, NuVasiveRichard Heyman, Ph.D., Seragon PharmaceuticalsJim Hinrichs, CareFusionElliot Hirshman, Ph.D., San Diego State UniversityMatthew Hudes, Deloitte LLPGuy J. Iannuzzi, MentusDavid Kabakoff, Ph.D., Sofinnova VenturesSteve Kaldor, Ph.D., QuanticelMichael Kamdar, Cellana, Inc.Katherine Kantardjieff, Ph.D., California State University San MarcosPaul Laikind, Ph.D., ViaCyteKevin Larkin, TherOxJacob Levin, Ph.D., UC Irvine

James LevineJack Lief, Arena Pharmaceuticals, Inc.*Steven Mento, Ph.D., Conatus Pharmaceuticals, Inc.*William Molloie, PwCPaul Negulescu, Ph.D., Vertex Pharmaceuticals, Inc.*Brian O’CallaghanKenneth Polin, Jones DayTrindl Reeves, Barney & Barney LLC*Gregory Reyes, M.D., Ph.D., CelgeneDan Ryan, Alexandria Real Estate EquitiesCamille Saltman, MD RevolutionJames Schaeffer, Ph.D., Merck Research Laboratories*Christophe Schilling, Ph.D., Genomatica, Inc.*Timothy Scott, Pharmatek Laboratories, Inc.*Martin Seidel, Ph.D., Genomics Institute of the Novartis Research FoundationBhasker Shetty, Ph.D.,Pfizer La JollaLarry Stambaugh*Mark Stevenson, Thermo Fisher Scientific *Scott N. Wolfe, Latham & WatkinsRandall E. Woods, Sophiris Bio*

LIFE DIRECTOR:Kennon W. Baldwin, Ferguson Pape Baldwin Architects*David Hale, Hale BioPharma Ventures*Tina Nova, Ph.D., Genoptix, Inc. A Novartis Company

Biocom Board Members-Ex-Officio:Sandra Brown, Ph.D., UCSDMark Cafferty, San Diego Regional Economic Development CorporationConstance Carroll, Ph.D., San Diego Community College DistrictScott Lippman, MD, Moores Cancer Center, UCSDPeter Preuss, The Preuss FoundationJerry Sanders, San Diego Regional Chamber of Commerce

*executive Committee member

Capital Development Committee*Carin Canale-Theakston, Canale Communications

David Kabakoff, Ph.D., Sofinnova Ventures

CRo Committee

Timothy Scott, Pharmatek Laboratories, Inc.

enviRonmental, HealtH anD Safety CommitteeCliff HannaDan Shiel, Pfizer La Jolla

faCilitieS CommitteeAndy Darragh, Ferguson Pape Baldwin Architects

Brent D. Jacobs, Cushman & Wakefield

fDa CommitteeMagda Marquet, Ph.D., Ajinomoto Althea Michele Yelmene, Pharmalink Consulting

intelleCtual pRopeRty anD patent law CommitteeMargaret Dunbar, Sanford-Burnham Medical Research Institute

Daniel Hart, Knobbe Martens Olson & Bear LLP

legiSlative CommitteeRichard LedfordApril Grant, Sunovion Pharmaceuticals

meDiCal DeviCe CommitteeNoel Gillespie, Procopio, Cory, Hargreaves& SavitchJoleen Schultz, Rady School of Management, UCSD

mHealtH CommitteeCamille Saltman, MD Revolution

publiC poliCy oveRSigHt Committee*Larry StambaughPaul Laikind, ViaCyte

puRCHaSing boaRD Committee*Jack Lief, Arena Pharmaceuticals, Inc.

SCHolaRSHip Committee

Bente Hansen, BenteHansen and Associates

bioCom inStitute boaRD Committee*Steven J. Mento, Ph.D., Conatus Pharmaceuticals, Inc.


bIoteChNoloGyAbgentAbide TherapeuticsAbwiz BioACADIA PharmaceuticalsActivX BiosciencesAdvanced BioMatrixAdvanced Targeting SystemsAerie PharmaceuticalsAfraxisAires PharmaceuticalsAllylixAM ChemicalsAMBRXAmgenAmicrobeAmplyx PharmaceuticalsAmylin PharmaceuticalsAnaptysBioAndroScienceApricus BiosciencesArcturus TherapeuticsArdea BiosciencesArrayomicsAstellas PharmaaTyr PharmaAuspex PharmaceuticalsAvantgenAvelasAviva BiosciencesBachem AmericasBioLegendBiomatricaBiomyxBioNano GenomicsBionomicsBio OptionsBioSpyder Technologies*BioTork

BioWaBoehringer-IngelheimCurtana PharmaceuticalsCalciMedicaCannaVest CorporationCARBOGEN AMCISCebixCell ApplicationsCelladonCellana Cell Signaling Technology*Center for Aquaculture TechnologiesCibusCoda TherapeuticsConju-ProbeContract BioticsCURx Pharmaceuticals*CustopharmDart NeuroscienceDenovo BiomarkersDSM Food SpecialtieseFFECTOR TherapeuticsElectronic BioScienceseMoleculesEpeius BiotechnologiesEquitech BioFabrusFate TherapeuticsFormexGenelux CorporationGenentechGenlantisGenoa PharmaceuticalsGenomaticaGenovo Corporation*GenSigniaGlaxoSmithKlineGuangdong Consun Pharmaceutical

Company*GWR Instruments

Halozyme TherapeuticsHarbor TherapeuticsHistogenHuya Bioscience InternationalIlluminaInception SciencesInhibrxInnoPepInnovative Cell TechnologiesInovio PharmaceuticalsIntegrated DNA TechnologiesIntercept PharmaceuticalsInternational Stem CellIntrepid TherapeuticsIntrinsic LifeSciencesInvetechInvivoGenIRBCo.ISIS PharmaceuticalsJaleva PharmaceuticalsJ-Oil MillsKalyra PharmaceuticalsKyowa Hakko Kirin CaliforniaLa Jolla BiologicsLa Jolla Pharmaceutical Company*Ligand PharmaceuticalsLitheraLpathLumena PharmaceuticalsMabVax TherapeuticsMast TherapeuticsMEI PharmaMeritage PharmaMonsantoNautilus EnvironmentalNaZura BioHealthNeuroGenetic PharmaceuticalsNitto Denko TechnicalNovartis PharmaceuticalsNoven Pharmaceuticals

Novo NordiskNucelisOcera TherapeuticsOptimum TherapeuticsOrexigen TherapeuticsOtonomyPacira PharmaceuticalsPanmira PharmaceuticalsPathway GenomicsPfenexPharmAkeaPolaris GroupPolynomaPolyPeptide GroupPredictive BiologyPreventice PrimaPharmPrimeGen BiotechPrognosys BiosciencesProSciQED BioscienceQuanticel PharmaceuticalsReceptosRegulus TherapeuticsREKA HealthRempex PharmaceuticalsRenova TherapeuticsRibomed BiotechnologiesRidgeline EngineeringRoche Applied Science*RQX PharmaceuticalsRuiYiSamumedSanguine BioSciencesSanofiScripps LaboratoriesSenju USASenomyxSentéSeragon Pharmaceuticals

SG BiofuelsShin Poong Pharmaceutical CompanySirenas Marine DiscoverySolstice BiologicsSoluLinkSophiris BioSorrento TherapeuticsSOVA PharmaceuticalsStemedica Cell TechnologiesSunovion PharmaceuticalsSynthetic GenomicsTakeda Pharmaceuticals U.S.A.Tanabe Research LaboratoriesTenova PharmaceuticalsThesan PharmaceuticalsTocagenTonbo BiosciencesTracon PharmaceuticalsTragara PharmaceuticalsTriphase AcceleratorTrius TherapeuticsUCBUS Specialty Labs*Vala SciencesVantari GeneticsVaxiion TherapeuticsVerdezyneVereniumVertex PharmaceuticalsVet-StemViaCyteVicalVital TherapiesWellspring BiosciencesWildcat Discovery Technologies Zensun USAZogenix

CroAbbiotecAbsorption SystemsAccelagenAccugent LaboratoriesAcurianAdvantar LaboratoriesAgility ClinicalAlliance Protein LaboratoriesAmbit BiosciencesAmerican Peptide CompanyAMRIAnnova ChemARIANNE

Behavioral PharmaBend ResearchBioAtlaCalChem SynthesisCato ResearchCharles River LaboratoriesChemDivConcortis Biosystems CytelligenDavos ChemicalEastern Clinical TrialsEastHorn Clinical Services EpistemeStudySiteExon BioSystems

Explora BioLabsGENEWIZGRAM LaboratoriesHamari Chemical San Diego Research

CenterHuntingdon Life SciencesIntegrium Clinical ResearchIriSysJadeBioMedinCellMicroConstantsMolecular ResponseMPI ResearchNeuroservice*OOxesis Biotech

PacificGMPPharPoint Research*Pharmatek LaboratoriesPPDPrescosProfil Institute For Clinical ResearchPSI CROPuracypQuadrants ScientificRetroViroxReveal BiosciencesRhoRobarts Clinical TrialsSAFC PharmaSeqWright Genomic Services

Sherpa Clinical PackagingStemgentSynteractHCRTherapeutics, Inc.Tioga ResearchToxikonTriligent InternationalUltimate LabsVerum.usVirapurWax-It Histology ServicesZyagen

premIumAbbVie*Ajinomoto AltheaAlexandria real estate equitiesArena PharmaceuticalsBayer healthcareBiomed realty trustBioserv CorporationBiospaceBP Biofuels

Cadence Pharmaceuticals*California manufacturing

technology ConsultingCanale CommunicationsCelgeneCoI PharmaceuticalsConatus PharmaceuticalsCooley LLPCounty of San Bernardino economic

development Agency

deloittedLA Pipereli Lillyernst & YoungFerring research InstituteFisher ScientificFoley & LardnerGe healthcare Life SciencesGenoptixhologic

Janssen research & developmentJones dayKPBSLatham & watkinsLife technologiesmentusmerck research Laboratories of

San diegomintz, Levin, Cohn, Ferris, Glovsky

and Popeo

NuVasivePatheonPfizerPraxair*PwCVwr Internationalwilson Sonsini Goodrich & rosati

bIoCom membershIp


NoN-prof I tAmerican Cancer Society, Border

Sierra RegionAmerican Red Cross - San DiegoCA Institute for Regenerative MedicineCalibrCalifornia Baptist University, College of

EngineeringCalifornia State University, San MarcosCity Of MuriettaCONNECTConsulate Of CanadaCSU,CSUPERB ProgramEscondido Union High School District*Foundation For Personal Financial

Education

Human BioMolecular Research Institute

Institute of Engineering in MedicineISM San DiegoJ. Craig Venter InstituteKaiser Permanente*KOTRA - Los AngelesLa Jolla Bioengineering InstituteLa Jolla Institute for Allergy &

ImmunologyLawrence Family Jewish Community

CenterLos Angeles Biomedical Research

InstituteMiraCosta College Biotech ProgramMt. San Jacinto CollegePhRMAPoint Loma Nazarene University

Quebec GovernmentRady School Of Management, UCSDSalk Institute For Biological StudiesSan Diego Clinical and Translational

Research Institute, UCSDSan Diego Community College DistrictSan Diego Employers Association*San Diego Natural History MuseumSan Diego Regional Chamber of

CommerceSan Diego Regional Economic

Development Corp.San Diego Supercomputer Center

(UCSD)San Diego Workforce PartnershipSan Diego Zoo GlobalSanford-Burnham Medical Research

Institute

Scottish Development InternationalScripps HealthScripps Research InstituteSwedish American Chamber Of

Commerce San DiegoThe BioIndustry AssociationThe Lowy Medical Research Institute

(LMRI)Torrey Pines Institute for Molecular

StudiesUC San Diego ExtensionUCI’s Office of ResearchUCSD, Department of BioengineeringUCSD, External Relations OfficeUCSD School of MedicineUCSD, Technology Transfer OfficeUK Trade & InvestmentUniversity of San Diego

INdIv IdualAntoinette AzevedoBernard KingCarol Gallagher*Elliot ParksGary FriedmanJohn KavanaghJulie AmesLarry StambaughPeter PreussRichard Ledford

* New members from october 2013 to January 2014

medIC al dev ICe & d IaGNost ICAcon LaboratoriesAethlon MedicalAlphatec SpineAltheaDxAmerica DiagnosticsApplied ProteomicsAstute MedicalAviirBeneChillBioceptBioDxBiological DynamicsbioTheranosticsBreathe TechnologiesBruin BiometricsCareFusion

Cell IdxCeloNova BioSciencesCelulaCliniqa CorporationClinMetCompellonCRISI Medical SystemsCritical DiagnosticsCTK BiotechCVAC SystemsCytori TherapeuticsDermTech InternationalDexComDiagnostic Consulting NetworkEllipse TechnologiesEnigma DiagnosticsEntra Health SystemsEpic SciencesEpitope Diagnostics

Fallbrook EngineeringFemCapFortimedix USAFreedom MeditechGenWay BiotechGlaukos CorporationGlysensHitachi Chemical Research CenterIchor Medical SystemsIgnytaImpediMedImThera MedicalInceptus MedicalINOVA DiagnosticsInterventional SpineInVision Biomedical GroupInvivoscribe TechnologiesIonian TechnologiesIvantis

Ivera MedicalKFx MedicalLiferiverMARDX DiagnosticsMD RevolutionMed SystemsMicell TechnologiesMillennium LaboratoriesNano Imaging ServicesOncoSec Medical OrganovoPrometheus LaboratoriesQualigenQuantum DesignQuidelReShape MedicalREVA MedicalReverse MedicalReVision Optics

Ridge DiagnosticsRoka BioscienceSequenomShireSienna LabsSirigenSonendo*SpectraScienceSuneva MedicalTandem DiabetesTargesonTensys MedicalTherOxTristan TechnologiesTrovageneUptake MedicalValor MedicalVertiFlexYulex

key provIderAirgasBarney & BarneyCushman & WakefieldOracle Health SciencesProcopio, Cory, Hargreaves & SavitchQualcommSan Diego Gas & Electric

provIder2ConnectAccelrysAIS (American Internet Services)AlphaGraphics of La JollaAMN HealthcareAssay DepotAustin CommercialBeckloff AssociatesBente Hansen & AssociatesBingham McCutchenBionest PartnersBiosourcesBioSurplusBiotech Primer

Biotech VendingBioTixBlue Sky BroadcastBootstrap IncubationBrinson Patrick SecuritiesCaliber Associates California Commercial SecurityCampbell AllianceCanteen Vending ServicesCB Richard EllisCenduitChina Business PartnersChubb Group of Insurance CompaniesClinigen HealthcareCompete ConsultingControlled Contamination ServicesCox Business*CymerDomain AssociatesEBD GroupElsevierEntereyEquipNetEuretosFerguson Pape Baldwin Architects

Fish & RichardsonFisher & PhillipsForward VenturesFrench Biobeach*Frequentz*GenslerGood & RobertsGrande ColonialGrant ThorntonHCP Life Science EstatesHyatt Regency La Jolla at AventineInnovative Commercial EnvironmentsInnovative Lease ServicesJ.T. MacMillan PhotographyJackson & Blanc HVAC ContractorsJones Lang LaSalle*KBM Facility SolutionsKilroy RealtyKnobbe, Martens, Olson & BearLeadership EdgeLegacy Partners CommercialLevementumLG Technology Center of AmericaManaged SolutionMayer Hoffman McCann

McKenna Long & AldridgeMission3Morgan, Lewis & BockiusMorrison & FoersterOccupational ServicesOffice DepotOfficeMax / Workplace InteriorsOgletree, Deakins, Nash, Smoak &

StewartOmniComm SystemsOxford FinancePegasus Cleanroom ServicesPharmalink ConsultingPR NewswirePrevost ConstructionProject Management AdvisorsPrudential Cleanroom ServicesRelocation CoordinatesRetirement DNASan Diego World Trade CenterSanford Rose Associates® - Toft GroupSartoriusSecureDocsScient Federal Credit Union* Sharp Business Systems

Sheppard Mullin Richter & HamptonShred San DiegoSilicon Valley BankSLM GroupSofinnova VenturesSonceboz Corporation Square 1 BankS Squared Executive Search*Stradling Yocca Carlson & RauthStudleySughrue MionTechnical Safety ServicesThe Business Cleaning CompanyThe HealthEd GroupThe Sandler GroupThomas, Mcnerney & PartnersT-Mobile USAUnited Parcel Service (UPS)Urban ContractingVDP DirectVeoliaVirgin AmericaVision33


For more information and to register:extension.ucsd.edu/lifesciences | (858) 534-9353 | [email protected] Discounts Available!

April 30-May 2, 2014 | 8:00 a.m. – 5:00 p.m. | UC San Diego Campus, La Jolla, CA

3-DAY EVENTMammalian Fermentation WorkshopThis 3-day workshop, developed in partnership between UC San Diego’s Center for Continuing Education in Biosciences (CCE|BIO) and UC San Diego Extension, is designed to provide participants with a deeper understanding of the performance of mammalian cell culture operations throughout the product and process life cycle from process development to full scale manufacturing under current Good Manufacturing Practices. This workshop combines practical knowledge with case studies to provide participants with the ability to thoroughly analyze experimental cell culture results.

• Learn about the history of mammalian cell biotechnology and challenges faced

• Gain an overview of the manufacturing process

• Explore key issues and tools used in industrial cell culture operations

• Develop a deeper understanding of technology transfer and scale-up

• Analyze experimental cell culture results using proper statistical analysis

SPEAKERS:

MICHAEL DAVID, PH.D. Professor Molecular BiologyUC San Diego

MICHAEL FINO, M.ENG. ProfessorBioprocess Technology MiraCosta College

MICHAEL POHLSCHEIDT, PH.D. DirectorManufacturing OperationsGenentech

ERIC M. FALLON, PH.D.DirectorTechnologyGenentech

GenentechSite VisitIncluded

4510 Executive Drive, Plaza OneSan Diego, CA 92121-3021

www.Biocom.org

Prsrt StdU.S. Postage

PAIDPermit #2325San Diego, CA

Please send a change of address or subscription request to Katelyn

Doyle at [email protected].

22 for the southern california life science community ...matsc.org/unprotected...

Documents